Bernice L. Brogdon

465 total citations
9 papers, 204 citations indexed

About

Bernice L. Brogdon is a scholar working on Pharmacology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Bernice L. Brogdon has authored 9 papers receiving a total of 204 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pharmacology, 3 papers in Molecular Biology and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Bernice L. Brogdon's work include Cannabis and Cannabinoid Research (4 papers), Neurotransmitter Receptor Influence on Behavior (2 papers) and Psychedelics and Drug Studies (2 papers). Bernice L. Brogdon is often cited by papers focused on Cannabis and Cannabinoid Research (4 papers), Neurotransmitter Receptor Influence on Behavior (2 papers) and Psychedelics and Drug Studies (2 papers). Bernice L. Brogdon collaborates with scholars based in United States. Bernice L. Brogdon's co-authors include Mingxin Qian, Steve E. Unger, Hang Zeng, Jing‐Tao Wu, Robert N. DeHaven, Karin Worm, James M. Trzăskos, Christopher J. LaBuda, Joel Cassel and James J.‐W. Duan and has published in prestigious journals such as Analytical Chemistry, Atherosclerosis and Drug Metabolism and Disposition.

In The Last Decade

Bernice L. Brogdon

8 papers receiving 190 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bernice L. Brogdon United States 7 88 76 47 40 29 9 204
Scott Reuschel United States 10 54 0.6× 107 1.4× 30 0.6× 15 0.4× 26 0.9× 16 245
Lisa Broske Italy 5 57 0.6× 64 0.8× 19 0.4× 39 1.0× 10 0.3× 7 170
Kazuhisa Takayama Japan 12 33 0.4× 94 1.2× 21 0.4× 22 0.6× 31 1.1× 19 415
Noel M. Meltzer United States 11 48 0.5× 156 2.1× 66 1.4× 13 0.3× 6 0.2× 16 378
Jerry Z. Yang United States 8 29 0.3× 103 1.4× 24 0.5× 14 0.3× 43 1.5× 9 293
Mette Guldbrandt Denmark 8 32 0.4× 159 2.1× 17 0.4× 13 0.3× 21 0.7× 9 365
Brad Ackermann United States 6 136 1.5× 98 1.3× 20 0.4× 18 0.5× 4 0.1× 6 268
John M. Hevko United States 7 152 1.7× 260 3.4× 35 0.7× 12 0.3× 7 0.2× 14 401
John P. Caldwell United States 13 24 0.3× 186 2.4× 31 0.7× 9 0.2× 47 1.6× 22 392

Countries citing papers authored by Bernice L. Brogdon

Since Specialization
Citations

This map shows the geographic impact of Bernice L. Brogdon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernice L. Brogdon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernice L. Brogdon more than expected).

Fields of papers citing papers by Bernice L. Brogdon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernice L. Brogdon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernice L. Brogdon. The network helps show where Bernice L. Brogdon may publish in the future.

Co-authorship network of co-authors of Bernice L. Brogdon

This figure shows the co-authorship network connecting the top 25 collaborators of Bernice L. Brogdon. A scholar is included among the top collaborators of Bernice L. Brogdon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernice L. Brogdon. Bernice L. Brogdon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Worm, Karin, Christopher T. Saeui, Joel Cassel, et al.. (2009). Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. Bioorganic & Medicinal Chemistry Letters. 19(17). 5004–5008. 6 indexed citations
2.
Bourdonnec, Bertrand Le, Karin Worm, Catherine Goodman, et al.. (2009). Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability. Bioorganic & Medicinal Chemistry Letters. 20(1). 387–391. 9 indexed citations
3.
Chu, Guo‐Hua, Christopher T. Saeui, Karin Worm, et al.. (2009). Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists. Bioorganic & Medicinal Chemistry Letters. 19(20). 5931–5935. 12 indexed citations
4.
Goodman, Catherine, Karin Worm, Bertrand Le Bourdonnec, et al.. (2008). CB2 selective sulfamoyl benzamides: Optimization of the amide functionality. Bioorganic & Medicinal Chemistry Letters. 19(2). 309–313. 14 indexed citations
5.
6.
Wu, Jing‐Tao, Hang Zeng, Mingxin Qian, Bernice L. Brogdon, & Steve E. Unger. (1999). Direct Plasma Sample Injection in Multiple-Component LC−MS−MS Assays for High-Throughput Pharmacokinetic Screening. Analytical Chemistry. 72(1). 61–67. 108 indexed citations
7.
Lai, Chii‐Ming, et al.. (1998). Determination of bisnafide, a novel bis-naphthalimide anticancer agent, in human plasma by high-performance liquid chromatography with UV detection. Journal of Pharmaceutical and Biomedical Analysis. 17(3). 427–434. 11 indexed citations
8.
Lai, Chii‐Ming, Bernice L. Brogdon, Check Y. Quon, & Henry J. Pieniaszek. (1994). Determination of DuP 128, an ACAT inhibitor and its sulphoxide and sulphone metabolites in human plasma by liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis. 12(9). 1163–1172. 1 indexed citations
9.
Lai, Chii‐Ming, Bernice L. Brogdon, Henry J. Pieniaszek, et al.. (1994). Pharmacokinetics and pharmacodynamics of the ACAT inhibitor DuP128 in man. Atherosclerosis. 109(1-2). 250–250. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott Reuschel Breakdown of academic impact, for papers by Lisa Broske Breakdown of academic impact, for papers by Kazuhisa Takayama Breakdown of academic impact, for papers by Noel M. Meltzer Breakdown of academic impact, for papers by Jerry Z. Yang Breakdown of academic impact, for papers by Mette Guldbrandt Breakdown of academic impact, for papers by Brad Ackermann Breakdown of academic impact, for papers by John M. Hevko Breakdown of academic impact, for papers by John P. Caldwell
Rankless by CCL
2026